Gelteq Limited GELS 深 滬
等待開盤 04-10 09:30:00 美东时间
0.7684
+0.105
+15.90%
華盛通- 最 高0.77
- 今 開0.6999
- 成交量 5.23万股
- 最 低 0.6865
- 昨 收 0.663
- 總市值 823.04万
- 52周最高 4.11
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6401
- 委 比 -96.24%
- 總股本 1071.11万
- 歷史最高 5.50
- 量 比 1.10
- 振 幅 12.59%
- 歷史最低 0.6401
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galmed Pharmaceuticals (NASDAQ:GLMD) stock increased by 83.2% to $1.14...
04-09 20:05
Gelteq and Healthy Extracts Sign MOU To Accelerate Gel-Based Product Rollouts
Healthy Extracts will serve as the primary manufacturer, commercial seller, and distribution partner for this range of products. Gelteq will provide the required technical transfer to enable manufacturing whilst
02-11 21:48
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
Gelteq and Healthy Extracts have signed a strategic partnership to accelerate the commercial rollout of next-generation gel-based nutraceutical products. Gelteq will provide its proprietary gel delivery technology, while Healthy Extracts will leverage its U.S.-based manufacturing capabilities for production and global distribution. The collaboration aims to meet growing demand for innovative delivery formats in nutrition and expand into new marke...
02-11 13:45
What's Driving Gelteq Ltd.'s (GELS) Over 69% After-Hours Surge?
Shares of Gelteq Ltd. jumped 69.25% in after-hours trading following the company's announcement of encouraging preclinical data for its cannabinoid oral gel platform.
01-14 12:01
Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
Gelteq Limited announces positive preclinical results showing its proprietary oral gel platform significantly enhances CBD absorption and bioavailability compared to oil-based products. The platform's improved bioavailability and convenience, along with reduced reliance on excipients, offers a safer and more efficient alternative for medicinal cannabis delivery. Leveraging Australia's Special Access Scheme (SAS), Gelteq aims to accelerate market ...
01-13 14:00
Gelteq Signs 3-Year China Distribution Deal With Mana To Expand Nutritional Product Portfolio; Expects To Derive A Minimum Revenue Of ~$1.3M During The Term Of The Agreement
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science based innovator in gel based oral delivery technologies, today announced that it has entered into a three year sales agreement with Shenzhen Mana Health
2025-12-09 22:16
Gelteq Announces Preclinical Results Showing That Its Proprietary Gel-Based Oral Delivery Formulation Significantly Improves The Bioavailability Of An Antihistamine Compared To A Leading Existing Product
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation
2025-11-24 21:34
Gelteq Announces Start Of A Preclinical Animal Trial With Monash University To Evaluate Its Proprietary Gel-Based Oral Delivery Technology For Oily And Poorly Soluble Drugs
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating its proprietary
2025-10-23 21:06
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
Gelteq Limited has commenced a preclinical animal trial with Monash University to evaluate its proprietary gel-based technology for improving the oral delivery of oily and poorly soluble drugs, addressing a major challenge in pharmaceutical development. Over 40% of marketed drugs and 90% of discovery candidates face solubility issues, leading to inconsistent outcomes. Gelteq aims to assist pharmaceutical partners through pipeline salvage, lifecyc...
2025-10-23 13:00
Gelteq Signs Product Development, Profit Share Agreement With Melbourne Health To Develop New Products Incorporating High-amylose Maize Starch Butyrylated
MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered
2025-10-09 20:11
